Eight Advisory advised Ypsomed AG on the sale of its pen needle and blood glucose monitoring business to MTD Medical Technology and Devices
Eight Advisory provided financial and carve-out services to Ypsomed AG in support of the sale of its pen needle and blood glucose monitoring business to MTD Medical Technology and Devices S.p.A.
Ypsomed, a leading developer and manufacturer in the field of self-medication and diabetes care, has carved-out and sold its pen needle and blood glucose monitoring systems (BGMs) business to MTD. With a global network of production sites and more than 2,200 employees worldwide, Ypsomed is a preferred partner of pharmaceutical and biotech companies and a renowned diabetes specialist.
With this divestment, Ypsomed is focusing its diabetes care business even more strongly on the further development and marketing of the innovative mylife Loop insulin pump solution.
MTD is a global manufacturer of medical devices for self-care and professional use. The medical technology group has over 16.000 clients and continuously expands its product portfolio by collaborating with pharma companies and innovative start-ups.
Eight Advisory team members supporting on this transaction:
- Financial Due Diligence: Patric Roth, Partner, Pál Blaskó, Senior Manager, Jan-Niklas Herden, Manager, and Gezim Gurgurovci, Analyst
- Carve-out services: Curt-Oliver Luchtenberg, Partner, Aaron Krüttgen, Director, and Maximilian Künstner, Senior
